Transforming Immunotherapy:

Targeting oxMIF in Cancer & Chronic Inflammation

oxMIF: we discovered it, we named it, we are drugging it

In recent years, significant advancements have tackled previously elusive therapeutic targets, with the potential to redefine patient care standards. OncoOne is at the forefront, with the groundbreaking discovery of oxMIF, an oxidized, disease-specific variant of the well-known yet enigmatic cytokine Macrophage Migration Inhibitory Factor (MIF). This breakthrough fuels our mission to harness the full potential of this ‘original cytokine’, aiming to enhance patient outcomes in cancer and inflammation via our innovative anti-oxMIF antibody pipeline.






Therapeutic Areas:

Targeting oxMIF in Cancer and Chronic Inflammation


OncoOne is developing ON203, an enhanced second-generation anti-oxMIF antibody, designed to address the treatment needs of patients facing solid tumors with substantial unmet medical requirements, encompassing tumors of the colon, lung, and ovaries. Its mechanism of action enables its use both as a monotherapy and in combination with standard-of-care treatments

Chronic Inflammation

OncoOne is currently advancing ON104, a novel second-generation anti-oxMIF antibody, tailored to address the therapeutic needs of patients living with chronic inflammatory and autoimmune disorders that have been significantly underserved. Its synergistic mechanism of action alongside glucocorticoids enables its utilization both as a monotherapy and in conjunction with lower doses of steroids.

Recent Publications

  • Ferhat M. et al. (2023) “The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis”, European Journal of Pharmacology, Volume 956, 5 October 2023, 175997. https://doi.org/10.1016/j.ejphar.2023.175997
  • Rossmueller, G. et al. (2023) ‘Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic’, Molecular Cancer Therapeutics, pp. OF1–OF15. https://doi: 10.1158/1535-7163.MCT-22-0676.